Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 18, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP14.92 per share, which was the price used for the re-investment of dividends paid on April 6, 2006.
Material Changes
The filing details an increase in shareholdings for specific individuals under the GlaxoSmithKline Annual Investment Plan. This increase resulted from the automatic re-investment of dividends. The filing does not report material changes to the company's overall financial position or operations compared to prior periods.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports on the compliance notification regarding the share transactions of the following individuals:
- Mr R Bondy (249 shares)
- Mr M Dunoyer (93 shares)
- Dr D Pulman (141 shares)
- Mr A Witty (87 shares)
- Mrs J Younger (216 shares)
Investor Verification Points
- Verify the total number of shares held by the named directors and managers following this transaction.
- Confirm the dividend payment date of April 6, 2006, and the associated re-investment terms.
- Note that this filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F for comprehensive financial metrics.